The Supreme Court on Monday revived the Federal Trade Commission's claim
that the multimillion-dollar settlements a drug company paid to keep
generic drugs off the market violated antitrust law.
The high court reversed the 11th Circuit's dismissal of a lawsuit challenging the settlement between Solvay Pharmaceuticals and generic drug makers.
Solvay makes and sells AndroGel, a patented testosterone-replacement gel. Though the Food and Drug Administration approved the drug in 2000, several companies began developing generic versions before Solvay was issued a patent in 2003.
Solvay then sued generic drug makers Watson Pharmaceuticals (now Actavis Inc.), Paddock Laboratories and Paddock's partner, Par Pharmaceutical Co., for allegedly infringing on its patent.
http://www.courthousenews.com/2013/06/17/58579.htm
The high court reversed the 11th Circuit's dismissal of a lawsuit challenging the settlement between Solvay Pharmaceuticals and generic drug makers.
Solvay makes and sells AndroGel, a patented testosterone-replacement gel. Though the Food and Drug Administration approved the drug in 2000, several companies began developing generic versions before Solvay was issued a patent in 2003.
Solvay then sued generic drug makers Watson Pharmaceuticals (now Actavis Inc.), Paddock Laboratories and Paddock's partner, Par Pharmaceutical Co., for allegedly infringing on its patent.
http://www.courthousenews.com/2013/06/17/58579.htm
No comments:
Post a Comment